Biological name

Borrelia Burgdorferi Bacterin

The only Lyme vaccine with a traditional isolate targeted at OspA and a unique isolate proven to induce high levels of borreliacidal antibodies to OspC.1

Features and benefits

The only Lyme vaccine designed to target the 2 key outer surface proteins (Osps) involved in disease transmission for a full level of protection.

  • Proven to induce borreliacidal antibodies that bind to OspA and OspC, forming a complex that attacks the cell membrane and kills Borrelia burgdorferi1,2
  • Proven to help prevent clinical disease such as arthritis2
  • Highly effective: no serologic evidence of exposure to B. burgdorferi2


  • For the vaccination of healthy dogs as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi
  • Recommended for use in healthy dogs 8 weeks of age or older

Safety information

Proven safe and well tolerated in a field safety trial of more than 600 dogs1

  • Less than 1% of dogs experienced vaccine-related adverse reactions
  • 99.3% reaction-free
  • No dogs removed from the study
  • Since 2009, Nobivac Lyme has been safely administered to over 2 million dogs

Dosage and administration

  • Subcutaneous injection
  • Two 1-mL doses given 2 to 4 weeks apart
  • Last dose may be given at 12 weeks of age
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS


  1. Data on file, Merck Animal Health.
  2. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol. 2009;16(2):253–259.

Article Here-